Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 14/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SPR | P35270 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339908 | 0.82 | SPR (0.65) | MTNR1AMTNR1BALDH1A1SPRBCHE | |
| SCHEMBL5341340 | 0.80 | MTNR1A (0.56) | MTNR1AMTNR1BALDH1A1SPRBCHE | |
| SCHEMBL7021034 | 0.80 | MTNR1A (0.52) | MTNR1AMTNR1BALDH1A1SPRBCHE | |
| SCHEMBL5340496 | 0.79 | SPR (0.55) | MTNR1AMTNR1BALDH1A1SPRBCHE | |
| SCHEMBL5339464 | 0.79 | SPR (0.55) | MTNR1AMTNR1BALDH1A1SPRBCHE | |
| SCHEMBL5335667 | 0.79 | SPR (0.55) | MTNR1AMTNR1BALDH1A1SPRBCHE | |
| SCHEMBL6076414 | 0.78 | SPR (0.60) | MTNR1AMTNR1BALDH1A1SPRBCHE | |
| SCHEMBL5335786 | 0.78 | SPR (0.49) | MTNR1AMTNR1BALDH1A1SPR | |
| SCHEMBL5340177 | 0.77 | MTNR1A (0.55) | MTNR1AMTNR1BALDH1A1SPRBCHE | |
| SCHEMBL6218623 | 0.76 | MTNR1A (0.52) | MTNR1AMTNR1BALDH1A1SPRBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | claimed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | MTNR1A 388/4885MTNR1B 325/4885ALDH1A1 1076/4885 |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP3A5, CYP4B1, MC2R | MTNR1A 409/4885MTNR1B 340/4885ALDH1A1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.